US Personalized Cancer Whole Genome Sequencing Market to Post 17.7% CAGR

Monday 24 September 2012, Amsterdam

According to a new report, the US Personalized Whole Genome Sequencing (WGS) Market has begun to mushroom and is expected to have a significant growth rate owing to the immense role it has been shown to play in personalized cancer treatment. Though still in infancy, players are actively strengthening their sequencing portfolio. Most players now provide variety of options extending from a coverage of >30x to de novo assembly, depending upon the kind of analysis required. Further, the players are enhancing their sequencers for reducing both the cost and turnaround time of their operations. Market players, such as Illumina, Complete Genomics, Beckman Coulter Genomics, Cofactor Genomics among others are poised to witness good growth in their revenues through personalized whole genome sequencing for diagnosing cancer. Moreover, it is estimated that the market for US Personalized Cancer Whole Genome Sequencing will grow at a healthy CAGR of around 17.7% during 2012-2016.

Research Analysis & Highlights

The report entitled, "US Personalized Cancer Genome Sequencing Market", provides an extensive research and in-depth analysis of the current status and expected position of the US market for personalized WGS intended for diagnosing cancer. It also evaluates the future potential of the market and focuses on the strengths and weaknesses of the market players.

Moreover, it illustrates the market drivers, key developments, and restraints that may impact the market in an effective manner. A brief description of the regulatory environment has also been provided.

Some of the report's key highlights include:

            - Rising cancer prevalence to drive the market.
            - Significant potential underlines the US personalized cancer WGS market.
            - Key constraints to overcome by the market players.